To include your compound in the COVID-19 Resource Center, submit it here.

QIDP for Motif's iclaprim triggers L22M placing

FDA granted Qualified Infectious Disease Product (QIDP) designation to iclaprim from Motif Bio plc (LSE:MTFB) to treat hospital-acquired bacterial pneumonia

Read the full 209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE